Palisade Bio (NASDAQ:PALI) Director Buys 20,000 Shares of Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 20,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were acquired at an average price of $2.05 per share, for a total transaction of $41,000.00. Following the acquisition, the director owned 386,904 shares of the company’s stock, valued at $793,153.20. This trade represents a 5.45% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Robert Jr. Baltera also recently made the following trade(s):

• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The shares were bought at an average cost of $2.03 per share, with a total value of $60,900.00.
• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.98 per share, for a total transaction of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Stock Performance

Shares of PALI traded down $0.03 during mid-day trading on Wednesday, reaching $2.05. 3,270,900 shares of the company were exchanged, compared to its average volume of 4,120,142. The business has a 50 day simple moving average of $1.91 and a two-hundred day simple moving average of $1.92. The stock has a market capitalization of $355.84 million, a PE ratio of -2.03 and a beta of 1.50. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts predict that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PALI. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Wolfe Research initiated coverage on Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price for the company. Oppenheimer set a $7.00 target price on Palisade Bio in a report on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Palisade Bio has a consensus rating of “Buy” and an average price target of $8.83.

Institutional Trading of Palisade Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC acquired a new position in Palisade Bio during the 4th quarter worth approximately $28,318,000. Commodore Capital LP acquired a new position in shares of Palisade Bio during the fourth quarter worth approximately $26,896,000. Janus Henderson Group PLC acquired a new position in shares of Palisade Bio during the fourth quarter worth approximately $24,822,000. RA Capital Management L.P. bought a new position in shares of Palisade Bio in the 4th quarter worth $16,742,000. Finally, Eversept Partners LP acquired a new stake in Palisade Bio in the 4th quarter valued at $12,670,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.